Granules India plans expansion
Granules India Ltd, the Hyderabad-based producer of active
pharmaceutical ingredients (API) and pharmaceutical formulation intermediates (PFI),
is expanding the capacity of its four existing plants and is also setting up two
The total cost of the project is estimated at $25 million of which $15 million
will be funded by IFC. The project will be funded through equity and long-term
loans, a company spokesperson said. The company has already raised $5 million
from Ridgeback Capital, $5 million from ISP NLC and $6 million from IFC as
long-term loans. The company is also in talks with IFC for another $9 million.
Among the two new projects, Granules India is setting up a six billion per annum
multi-product tableting plant at its existing Gagillapur facility near
Hyderabad, which is the world's single-largest multi-product granulation plant.
The company is also setting up a 3,600-tpa paracetamol API plant at its existing
paracetamol unit at Bonthapally. The third existing unit is located at
The company is installing an additional 3,600 tpa of paracetamol PFI capacity at
its Bonthapally unit. It has also invested in a joint venture in China for
ibuprofen API with a capacity of 3,800 tpa, which is expected to start
commercial production in July this year. The company also plans to expand its
R&D facility from 3,500 sq. ft to 7,000 sq. ft by mid-2007.
Contact: Granules India Ltd, 8-2-293/A/A/2, Road No.2,
Banjara Hills, Hyderabad, Andhra Pradesh 500033.
Tel: 040-23553266; Fax: 040-23547894; E-mail: email@example.com
[14 May 2007]